Drug Discovery
Revolutionizing Drug Discovery: The Evolution from Target-Selective Design to AI-Powered Polypharmacology
Drug Discovery, Target-Selective Design, AI-Enabled Polypharmacology, Machine Learning, Systems Biology, Multi-Target Drugs, Personalized Medicine.
Revolutionizing Protein Design: Nabla Bio Secures $26M for AI-Driven Pharmaceutical Solutions
Nabla Bio, genAI protein design, funding, pharmaceutical partners, biotechnology, protein engineering, drug discovery, artificial intelligence, healthcare innovation.
Revolutionizing Pharmaceuticals: Nabla Bio Secures $26M for AI-Powered Protein Design
Nabla Bio, generative AI, protein design, funding, pharmaceutical partners, biotechnology, drug discovery.
Revolutionizing Biology: AlphaFold 3 by Isomorphic and DeepMind Expands Beyond Protein Predictions
AlphaFold 3, Isomorphic, DeepMind, protein predictions, biology revolution, artificial intelligence, machine learning, structural biology, drug discovery, disease research.
Xaira: The Billion-Dollar AI-Powered Drug Discovery Startup Revolutionizing Healthcare
Xaira, AI, drug discovery, healthcare, startup, funding, billion-dollar, revolutionizing, pharmaceuticals, biotechnology.
BenevolentAI Downsizes Operations, Cuts 30% of Workforce Amidst Funding Challenges
BenevolentAI, layoffs, workforce reduction, funding gap, US site closure, AI research, drug discovery
BenevolentAI Announces Significant Restructuring with Workforce Reduction and US Office Closure
BenevolentAI, restructuring, workforce reduction, US office closure, reset, artificial intelligence, biotechnology, drug discovery
Boehringer Ingelheim and Ochre Bio Join Forces in a $1 Billion Collaboration to Combat Chronic Liver Diseases
Boehringer Ingelheim, Ochre Bio, collaboration, chronic liver diseases, $1 billion, drug discovery, RNA therapeutics, liver fibrosis, non-alcoholic steatohepatitis (NASH)
Ipsen and Skyhawk Therapeutics Join Forces in a $1.8 Billion Deal to Advance RNA Modulator Research
Ipsen, Skyhawk Therapeutics, RNA modulators, drug discovery, partnership, $1.8 billion, biopharmaceutical, R&D, therapeutic development